斯沃(利奈唑胺)临床药理及PK PD临床应用与疗效.ppt

《斯沃(利奈唑胺)临床药理及PK PD临床应用与疗效.ppt》由会员分享，可在线阅读，更多相关《斯沃(利奈唑胺)临床药理及PK PD临床应用与疗效.ppt（29页珍藏版）》请在优知文库上搜索。

1、 O N C 3 H F O H C N O O N 12.51.Adapted from Honeybourne D,et al.J Antimicrob Chemother.2003;51:1431-4 and erratum 2003;52;536.2.Gee T,et al.Antimicrob Agents Chemother.2001;45:1843-6.3.Lovering AC,et al.J Antimicrob Chemother.2002;50:73-7.4.Pfizer Inc.,data on file.5.Gendjar SR,et al.ASN/ISN WCN 2

2、001,Abstract 2205.1.Graziani 1988;2.Matzke 1986;3.Albanese 2000;4.Georges 1997;5.Lamer 1993;6.Daschner 1987;7.Blevins 1984;8.Wilson 2000;9.Stahl 1987;10.Wise 1986;11.Frank 1997;12.Lovering 2002;13.SmPC;14.Gee 2001;15.Gendjar 2001.斯沃的药代动力学斯沃的药代动力学代谢代谢1.Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumoniaCrit Care Med 2005 Vol.33,No.7 P1529-15332.Intrapulmonary penetration of linezolid.Journal of Antimicrobial Chemotherapy(2003)51,14311434斯沃在斯沃在12小时的给药间期内小时的给药间期内药物浓度始终高于药物浓度始终高于金黄色葡萄球菌金黄色葡萄球菌MIC90AUC/MIC